Treatment Results of Adjuvant Chemotherapy after Radical Hysterectomy for Intermediate-Risk Stage IB-IIB Cervical Cancer

Hongwu Wen^1*, Tongyu Liu², Zhaoyi Feng¹, Weiping Huang³, Ke Ma⁴, Xia Tao¹

¹Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, China.
²Department of Gynecology, Fujian Provincial Tumor Hospital, Fuzhou, China.
³Department of Obstetrics and Gynecology, The Fifth Hospital of Shijiazhuang, Shijiazhuang, China.
⁴Department of Obstetrics & Gynecology, Beijing Tsinghua Changgung Hospital Medical Center, Tsinghua University, Beijing, China.

DOI: 10.4236/jct.2015.612117                

Abstract

Objective: The objective is to evaluate the effectiveness of chemotherapy as postoperative adjuvant therapy for stage IB-IIB cervical cancer with intermediate-risk factors. Methods: We retrospectively reviewed the medical records of 119 cervical cancer patients with intermediate-risk factors treated with radical hysterectomy and pelvic lymphadenectomy from December 1997 to September 2010. The intermediate-risk factors included bulky tumor (≥4 cm), lymphovascular space invasion, and deep stromal invasion. Sixteen patients did not receive adjuvant therapy (observation group); 73 were treated with chemotherapy (CT group); 30 were treated with adjuvant radiation therapy (RT group). The significance of the clinical parameters, 3- and 5-year overall survival (OS) rates of each group, was analyzed. Results: The 3- and 5-year OS rates between the observation group and adjuvant therapy group (CT plus RT groups) were not statistically different (3-year OS: 100% and 94.4%, respectively; 5-year OS: 100% and 92.3%, respectively; p > 0.05). The 3- and 5-year OS rates between the CT group and RT group were also not statistically different (3-year OS: 93.6% and 96.4%, respectively; 5-year OS: 80.7% and 96.4%, respectively; p < 0.05). Univariate and multivariate analysis of survival indicated that different adjuvant therapies were not independent prognostic indicators for IB-IIB cervical cancer patients with intermediate-risk factors. Conclusions: CT may have equivalent therapeutic effect as RT for stage IB-IIB cervical cancer patients with intermediate-risk factors after radical surgery, and prospective randomized trial is needed to study the effect of CT in these patients.

Keywords

Cervical Cancer, Chemotherapy, Radiotherapy, Prognosis

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Nam, J.H., Park, J.Y., Kim, D.Y., et al. (2012) Laparoscopic versus Open Radical Hysterectomy in Early-Stage Cervical Cancer: Long-Term Survival Outcomes in a Matched Cohort Study. Annals of Oncology, 23, 903-911. http://dx.doi.org/10.1093/annonc/mdr360
[2]	Park, J.Y., Kim, D.Y., Kim, J.H., et al. (2011) Outcomes after Radical Hysterectomy According to Tumor Size Divided by 2-cm Interval in Patients with Early Cervical Cancer. Annals of Oncology, 22, 59-67. http://dx.doi.org/10.1093/annonc/mdq321
[3]	Song, S., Song, C., Kim, H.J., et al. (2012) 20-Year Experience of Postoperative Radiotherapy in IB-IIA Cervical Cancer Patients with Intermediate Risk Factors: Impact of Treatment Period and Concurrent Chemotherapy. Gynecologic Oncology, 124, 63-67. http://dx.doi.org/10.1016/j.ygyno.2011.09.033
[4]	Garg, G., Shah, J.P., Toy, E.P., et al. (2011) Stage IIA1 versus Stage IIA2 Cervical Cancer: Does the New Staging Criteria Predict Survival? International Journal of Gynecological Cancer, 21, 711-716. http://dx.doi.org/10.1097/IGC.0b013e3182138648
[5]	Peters, W.A., Liu, P.Y., Barrett, R.J., et al. (2000) Concurrent Chemotherapy and Pelvic Radiation Therapy Compared with Pelvic Radiation Therapy Alone as Adjuvant Therapy after Radical Surgery in High-Risk Early-Stage Cancer of the Cervix. Journal of Clinical Oncology, 18, 1606-1613. http://dx.doi.org/10.1097/00006254-200008000-00017
[6]	Lahousen, M., Haas, J., Pickel, H., et al. (1999) Chemotherapy versus Radiotherapy versus Observation for High-Risk Cervical Carcinoma after Radical Hysterectomy: A Randomized, Prospective, Multicenter Trial. Gynecologic Oncology, 73, 196-201. http://dx.doi.org/10.1006/gyno.1999.5343
[7]	Curtin, J.P., Hoskins, W.J., Venkatraman, E.S., et al. (1996) Adjuvant Chemotherapy versus Chemotherapy plus Pelvic Irradiation for High-Risk Cervical Cancer Patients after Radical Hysterectomy and Pelvic Lymphadenectomy (RH-PLND): A Randomized Phase III Trial. Gynecologic Oncology, 61, 3-10. http://dx.doi.org/10.1006/gyno.1996.0087
[8]	Iwasaka, T., Kamura, T., Yokoyama, M., et al. (1998) Adjuvant Chemotherapy after Radical Hysterectomy for Cervical Carcinoma: A Comparison with Effects of Adjuvant Radiotherapy. Obstetrics & Gynecology, 91, 977-981. http://dx.doi.org/10.1016/S0029-7844(98)00079-9
[9]	Takeshima, N., Umayahara, K., Fujiwara, K., et al. (2006) Treatment Results of Adjuvant Chemotherapy after Radical Hysterectomy for Intermediate- and High-Risk Stage IB-IIA Cervical Cancer. Gynecologic Oncology, 103, 618-622. http://dx.doi.org/10.1016/j.ygyno.2006.04.019
[10]	Hosaka, M., Watari, H., Takeda, M., et al. (2008) Treatment of Cervical Cancer with Adjuvant Chemotherapy versus Adjuvant Radiotherapy after Radical Hysterectomy and Systematic Lymphadenectomy. The Journal of Obstetrics and Gynaecology Research, 34, 552-556. http://dx.doi.org/10.1111/j.1447-0756.2008.00739.x
[11]	Lee, K.B., Lee, J.M., Ki, K.D., et al. (2008) Comparison of Adjuvant Chemotherapy and Radiation in Patients with Intermediate Risk Factors after Radical Surgery in FIGO Stage IB-IIA Cervical Cancer. International Journal of Gynecological Cancer, 18, 1027-1031. http://dx.doi.org/10.1111/j.1525-1438.2007.01136.x